TURKISH JOURNAL OF ONCOLOGY 2023 , Vol 38 , Num 4
Current Status of Stereotactic Radiotherapy in Türkiye: Turkish Society for Radiation Oncology Stereotactic Radiotherapy Study Group 10-006 Survey
Sümerya DURU BIRGI1,Menekşe TURNA2,Hale Başak ÇAĞLAR2,Berna AKKUŞ YILDIRIM3,Sezin YÜCE SARI4,Serap AKYÜREK1,Enis ÖZYAR5
1Department of Radiation Oncology, Ankara University Faculty of Medicine, Ankara-Türkiye
2Department of Radiation Oncology, Anadolu Medical Center Hospital, İstanbul-Türkiye
3Department of Radiation Oncology, University of Health Sciences, Prof. Dr. Cemil Taşçıoglu City Hospital, İstanbul-Türkiye
4Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara-Tür
5Department of Radiation Oncology, Acıbadem Maslak Hospital, İstanbul-Türkiye
DOI : 10.5505/tjo.2023.4134 OBJECTIVE
Stereotactic radiotherapy (SRT)/Stereotactic body radiotherapy (SBRT) constitutes extensively employed therapeutic modalities for various cancer types in our country, offering precise and conformal delivery of high radiation doses. This survey aims to analyze the current status of SRT/SBRT in our country.

METHODS
A total of 34 questions were asked by an online survey through Google Forms (SurveyMonkey) in October 2021. This nationwide survey focused on the demographic information of participants, SRT application techniques, treatment planning, and the utilization of SRT in clinical practice.

RESULTS
The survey was completed by a total of 106 respondents. A predominant number of participants belonged to the 40-50 age group, with <10 years of experience. Linear accelerators (92%) were the most common devices used for SRT, followed by CyberKnife (27%), Gamma Knife (5%), and Magnetic resonance imaging-Linac (3%). Combined kilovolt/megavolt portal imaging with cone-beam computed tomography (CBCT) was the most commonly used imaging verification method (58%). Treatments typically began within 2-7 days (76%) after simulation. The number of patients treated with SRT/SBRT over the past year varied in a wide range, with a median of 50 (range: 0-1000) patients. SRT/SBRT was applied in many cancer types including mostly brain (98%), lung (89%), bone (89%), adrenal (64%), liver (47%), prostate (42%), head and neck (41%), pancreas (35%), and other tumors (3%).

CONCLUSION
SRT/SBRT applications in our country vary in terms of number, experience, and treated tumor groups. These results are crucial for understanding the current status of SRT, treatment indications, challenges, and diversity in application approaches in our country. Keywords : Cancer; stereotactic body radiotherapy; stereotactic radiotherapy; survey